BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 28444728)

  • 1. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A circulating subset of BRAF
    Poch R; Le Louet S; Hélias-Rodzewicz Z; Hachem N; Plat G; Barkaoui MA; Lapillonne H; Delhommeau F; Emile JF; Donadieu J; Héritier S
    Br J Haematol; 2021 Aug; 194(4):745-749. PubMed ID: 34312844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between clinicopathologic characteristics and BRAF
    Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
    Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
    Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
    Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].
    Tang X; Guo X; Sun LY; Ai Y; Yang X; Sun JJ; Wu JR; Gao J
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Apr; 20(4):290-294. PubMed ID: 29658453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.
    Donadieu J; Larabi IA; Tardieu M; Visser J; Hutter C; Sieni E; Kabbara N; Barkaoui M; Miron J; Chalard F; Milne P; Haroche J; Cohen F; Hélias-Rodzewicz Z; Simon N; Jehanne M; Kolenova A; Pagnier A; Aladjidi N; Schneider P; Plat G; Lutun A; Sonntagbauer A; Lehrnbecher T; Ferster A; Efremova V; Ahlmann M; Blanc L; Nicholson J; Lambilliote A; Boudiaf H; Lissat A; Svojgr K; Bernard F; Elitzur S; Golan M; Evseev D; Maschan M; Idbaih A; Slater O; Minkov M; Taly V; Collin M; Alvarez JC; Emile JF; Héritier S
    J Clin Oncol; 2019 Nov; 37(31):2857-2865. PubMed ID: 31513482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
    Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
    Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
    Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.
    Tatsuno M; Shioda Y; Iwafuchi H; Yamazaki S; Iijima K; Takahashi C; Ono H; Uchida K; Okamura O; Matubayashi M; Okuyama T; Matsumoto K; Yoshioka T; Nakazawa A
    Diagn Pathol; 2016 Apr; 11():39. PubMed ID: 27094161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of BRAF V600E mutation in radiological Langerhans cell histiocytosis-associated neurodegenerative disease using droplet digital PCR analysis.
    Shimizu S; Sakamoto K; Kudo K; Morimoto A; Shioda Y
    Int J Hematol; 2023 Jul; 118(1):119-124. PubMed ID: 37010809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.
    Méhes G; Irsai G; Bedekovics J; Beke L; Fazakas F; Rózsa T; Kiss C
    Am J Surg Pathol; 2014 Dec; 38(12):1644-8. PubMed ID: 25118810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis.
    Morimoto A; Oh Y; Nakamura S; Shioda Y; Hayase T; Imamura T; Kudo K; Imashuku S;
    Cytokine; 2017 Sep; 97():73-79. PubMed ID: 28582647
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Wang CJ; Cui L; Ma HH; Wang D; Zhang L; Lian HY; Li WJ; Zhang Q; Wang TY; Li ZG; Zhang R
    Mol Cancer Ther; 2021 Jul; 20(7):1316-1323. PubMed ID: 33879554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Prevalence of
    Liu X; Zhang Y; Zhou CX
    Int J Surg Pathol; 2019 Dec; 27(8):836-843. PubMed ID: 31203679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases.
    Roden AC; Hu X; Kip S; Parrilla Castellar ER; Rumilla KM; Vrana JA; Vassallo R; Ryu JH; Yi ES
    Am J Surg Pathol; 2014 Apr; 38(4):548-51. PubMed ID: 24625419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival.
    Bhatia P; Singh M; Sharma M; Sharma A; Kakkar N; Radhika S; Trehan A; Bansal D
    Blood Cells Mol Dis; 2020 May; 82():102356. PubMed ID: 32171112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ddPCR Analysis Reveals BRAF V600E Mutations Are Infrequent in Isolated Pituitary Langerhans Cell Histiocytosis Patients.
    Nellan A; Bodlak A; Mirsky DM; Mulcahy Levy J; Garrington TP; Foreman NK; Gilani A; Hayashi M
    J Neuropathol Exp Neurol; 2020 Dec; 79(12):1313-1319. PubMed ID: 32930721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of BRAF-Inhibitor Therapy in BRAF
    Hazim AZ; Ruan GJ; Ravindran A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
    Oncologist; 2020 Dec; 25(12):1001-1004. PubMed ID: 32985015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.